Spots Global Cancer Trial Database for Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer
Official Title: Recombinant Anti-EGFR Monoclonal Antibody（SCT200） in Patients With Advanced Squamous Non-small Cell Lung Cancer : a Phase Ib, Open-label, Multicenter Study
Study ID: NCT03808701
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced squamous non-small cell lung cancer treated after failure of Two chemotherapy regimens (including Platinum-based drugs).
Detailed Description: This open label multicenter phase Ib study is designed to evaluate Objective Response Rate (ORR) in Squamous non-small cell Lung cancer treated with anti-EGFR monoclonal antibody SCT200.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: CHENG YING, MD
Affiliation: Jilin provincial cancer hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
